RFA-GM-22-001: IDeA Regional Entrepreneurship Development (I-RED) Program (STTR) (UT2 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $252,000 to small businesses. Applications closed on January 5, 2022.
From the official notice on Grants.gov, last changed October 7, 2021. Checked November 7, 2026.
- Award ceiling$252,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUT2
- Clinical trialsNot allowed
- Funded byNIGMS
- Median yearly award$1.5 million
- Typical project length3.5 years
Projects funded under RFA-GM-22-001 were run by National Institute of General Medical Sciences (NIGMS, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-GM-22-001 in the NIH Guide.
Key dates
| Posted | October 7, 2021 |
|---|---|
| Deadline | January 5, 2022 |
| Archived by Grants.gov | February 10, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.5 million; it allows up to $252,000 per award.
- Most of the program's money (80% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to provide opportunities for eligible U.S. small business concerns (SBCs), together with academic partners, in each of the four regions of the Institutional Development Award (IDeA)-eligible states, to apply forIDeA Regional Entrepreneurship Development (I-RED) program awards that support the development of educational products to promote biomedical entrepreneurship in IDeA states. These educational products are expected to address the needs of IDeA state academic institutions in developing and/or strengthening technology transfer programs that stimulate technological innovation and the needs of IDeA state investigators in translating scientific discoveries and technologies from research laboratories into commercial products that improve human health and promote economic growth in IDeA states.
Funded under RFA-GM-22-001 so far
NIH funded 3 projects under RFA-GM-22-001 in fiscal 2022 to 2024, at 3 institutions. The median yearly award was $1.5 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| STARTUP Central | Continuum Educational Technologies, PBC | 2024 | $1.5 million |
| Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States | New Mexico Start-Up Factory II, LLC | 2024 | $1.5 million |
| I-RED Southeast XLerator Network | Xleratehealth, LLC | 2024 | $1.5 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-GM-22-001 still open?
No. It closed on January 5, 2022.
Who can apply for IDeA Regional Entrepreneurship Development (I-RED) Program (STTR) (UT2 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for IDeA Regional Entrepreneurship Development (I-RED) Program (STTR) (UT2 Clinical Trial Not Allowed)?
Closed January 5, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $252,000 each.
Who has been funded under RFA-GM-22-001?
NIH RePORTER lists 3 projects funded under RFA-GM-22-001 in fiscal 2022 to 2024, at 3 institutions. The most were at Continuum Educational Technologies, PBC, New Mexico Start-Up Factory II, LLC, Xleratehealth, LLC.
Who has won Biomedical Research and Research Training grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, Regents of the University of Michigan, University of California, San Diego. The program made 11,631 awards worth $15 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)